Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 9,657 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 9,657 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the transaction, the chief executive officer owned 287,218 shares in the company, valued at approximately $2,854,946.92. This trade represents a 3.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Randy Teel also recently made the following trade(s):

• On Monday, February 23rd, Randy Teel sold 4,786 shares of Arvinas stock. The shares were sold at an average price of $12.16, for a total value of $58,197.76.
• On Friday, February 13th, Randy Teel sold 4,403 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total value of $52,351.67.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $9.87 on Thursday. The stock’s 50-day moving average is $11.14 and its 200-day moving average is $11.69. The company has a market cap of $636.81 million, a P/E ratio of -2.97 and a beta of 1.79. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $14.51.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The business had revenue of $15.60 million for the quarter, compared to the consensus estimate of $16.61 million. During the same period last year, the business earned $1.14 earnings per share. The firm’s revenue for the quarter was down 91.7% compared to the same quarter last year. As a group, equities analysts predict that Arvinas, Inc. will post -3.29 EPS for the current year.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18.00 from $16.00 and reiterated a Buy rating, signaling confidence in meaningful upside from current levels. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug VEPPANU (vepdegestrant) was licensed to Rigel Pharmaceuticals, with the deal including $85 million upfront plus up to $320 million in milestones. That provides validation for Arvinas’ PROTAC platform and adds potential future non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: Arvinas reported Q1 earnings of -$0.90 per share, slightly better than estimates, but revenue of $15.6 million missed expectations and fell sharply from last year, underscoring that profitability is still distant. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: CEO Randy Teel, CFO Andrew Saik, CAO David K. Loomis, and insider Noah Berkowitz all sold shares, though the filings indicate the sales were mainly for tax withholding tied to equity vesting. While routine, insider sales can still weigh on sentiment. CEO insider filing

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Friday, April 10th. Citigroup boosted their price objective on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Truist Financial set a $10.00 price objective on shares of Arvinas in a research report on Wednesday, March 18th. Wall Street Zen cut shares of Arvinas from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Arvinas currently has a consensus rating of “Hold” and an average target price of $15.14.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its stake in shares of Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after acquiring an additional 3,500 shares during the last quarter. State of Wyoming bought a new stake in shares of Arvinas in the 3rd quarter valued at about $68,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Arvinas in the 3rd quarter valued at about $92,000. Finally, Jain Global LLC bought a new stake in shares of Arvinas in the 3rd quarter valued at about $95,000. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.